| Presti, Rachel |
RSV OA=ADJ-023, NCT05921903: A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above |
|
|
| Active, not recruiting | 2 | 387 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA Investigational Vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 07/24 | 06/25 | | |
| Completed | N/A | 8 | US | Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content | Washington University School of Medicine, Janssen Scientific Affairs, LLC | HIV I Infection, Adiposity | 06/23 | 06/23 | | |
| Klebert, Michael K |
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B |
|
|
| Completed | 3 | 640 | US, RoW | HEPLISAV-B, ENGERIX-B | National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation | HIV Infection, Hepatitis B | 08/24 | 08/24 | | |
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE |
|
|
| Active, not recruiting | 3 | 310 | US | Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 11/24 | 08/26 | | |
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV |
|
|
| Completed | 2 | 110 | US | CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg | National Institute of Allergy and Infectious Diseases (NIAID), AbbVie | HIV-1-infection | 06/24 | 06/24 | | |
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV |
|
|
| Not yet recruiting | 2 | 186 | US, RoW | Pramipexole ER, Escitalopram | National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd. | Major Depressive Disorder, Mild Neurocognitive Disorder, HIV | 12/26 | 12/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 |
|
|
| Recruiting | 1/2 | 45 | US, RoW | ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences | HIV-1-infection | 04/28 | 08/29 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
NCT05144386: Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART |
|
|
| Completed | 1 | 6 | US | EBT-101 | Excision BioTherapeutics | HIV-1-infection | 11/24 | 11/24 | | |
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption |
|
|
| Recruiting | 1 | 46 | US | N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074 | National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc. | HIV Infection | 06/26 | 12/26 | | |
| Completed | N/A | 8 | US | Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content | Washington University School of Medicine, Janssen Scientific Affairs, LLC | HIV I Infection, Adiposity | 06/23 | 06/23 | | |
